Labour MP Luciana Berger slammed Corbyn on Twitter, writing: “The video released today of the leader of Labour making inexcusable comments – defended by a party spokesman – makes me as a proud British Jew feel unwelcome in my own party. I’ve lived in Britain all my life and I don’t need any lessons in history/irony.” The head of external affairs at Jewish education and training institution World ORT, Marcus Dysch, added: “Unambiguous antisemitic hate from Corbyn, a terrorist-sympathising, purge-orchestrating, fear-mongering, unaccountable, piece of work who should never have been allowed to lead a once-great party. Is it any wonder British Jews despair as this saga drags on?” Chair of the Jewish Leadership Council Jonathan Goldstein also had choice words for the Labour leader. “So Jeremy Corbyn believes that British Zionists (for which read Jews) do not possess normal British characteristics,” he tweeted. “The only thing ‘un- British’ are Mr Corbyn’s views. His politics do not reflect the tolerance, fairness and inclusivity from which we have all benefitted.”A Labour spokesperson said: “Jeremy is totally opposed to all forms of antisemitism and is determined to drive it out from society. At this event, he was referring to a group of pro-Israel activists misunderstanding and then criticising the Palestinian ambassador for a speech at a separate event about the occupation of the West Bank.” Share Friday 24 August 2018 12:08 pm The antisemitism row engulfing Labour took another turn after a video emerged of Labour leader Jeremy Corbyn saying certain Zionists had “no sense of English irony”. The video, which was published by the Daily Mail yesterday, shows comments Corbyn made at a 2013 conference that was reportedly promoted by Hamas’ website.  whatsapp Josh Mines Jeremy Corbyn faces backlash over comments about UK Zionists whatsapp This was dutifully recorded by the, thankfully silent, Zionists who were in the audience on that occasion, and then came up and berated him afterwards for what he had said. They clearly have two problems. One is they don’t want to study history, and secondly, having lived in this country for a very long time, probably all their lives, they don’t understand English irony either.They needed two lessons, which we could perhaps help them with. More From Our Partners Native American Tribe Gets Back Sacred Island Taken 160 Years Agogoodnewsnetwork.orgInside Ashton Kutcher and Mila Kunis’ not-so-average farmhouse estatenypost.comA ProPublica investigation has caused outrage in the U.S. this weekvaluewalk.comKiller drone ‘hunted down a human target’ without being told tonypost.comRussell Wilson, AOC among many voicing support for Naomi Osakacbsnews.comAstounding Fossil Discovery in California After Man Looks Closelygoodnewsnetwork.orgMatt Gaetz swindled by ‘malicious actors’ in $155K boat sale boondogglenypost.comBrave 7-Year-old Boy Swims an Hour to Rescue His Dad and Little Sistergoodnewsnetwork.orgPolice Capture Elusive Tiger Poacher After 20 Years of Pursuing the Huntergoodnewsnetwork.org Referring to a speech in parliament by Palestinian ambassador Manuel Hassassian on the history of Palestine, Corbyn said a group of Zionists surrounded the speaker and “berated” him afterwards. In the video, Corbyn says:  read more

first_imgRefinitiv itself is still tied up in talks with the London Stock Exchange over a blockbuster $27bn takeover bid. The acquisition comes at a pivotal time given the growth of due diligence services as businesses tackle new challenges due to the pandemic, including supply chain resilience, as well as increased focus on ESG due diligence. (Photo: Getty images) Also Read: Refinitiv buys the Red Flag Group as it expands due diligence offering Share Angharad Carrick whatsapp Monday 5 October 2020 6:51 pm Europe’s competition regulator has voiced concerns that London’s bond-trading platform MTS and Refinitiv, which owns bond platform Tradeweb, would have too large a market share. (Photo: Getty images) Also Read: Refinitiv buys the Red Flag Group as it expands due diligence offering Refinitiv said the addition of the Red Flag Group’s services will add to its existing due diligence capabilities and result in a “comprehensive set of tools and services to assist in customer and third-party risk mitigation”. EU antitrust regulators will make a decision on the bid on 16 December after resuming their investigation into the deal. “We chose to join Refinitiv because they offer the prospect of further growth and investment,” said Scott Lane, Founder and chief executive of The Red Flag Group. “The opportunity to build an extensive suite of due diligence products and capabilities to better serve our growing customer base is an exciting prospect.” Refinitiv said it was “expanding its suite of due diligence offerings” with the acquisition of what it described as a “leading provider of workflow, data, due diligence and ratings solutions”. Ad Unmute by Taboolaby TaboolaSponsored LinksSponsored LinksPromoted LinksPromoted LinksYou May LikeDaily FunnyFemale Athlete Fails You Can’t Look Away FromDaily FunnyUndobonvoyaged.comThese Celebs Are Complete Jerks In Real Life.bonvoyaged.comUndoNoteableyAirport Security Couldn’t Believe These Jaw-Dropping MomentsNoteableyUndoJustPerfact USAMan Decides to File for Divorce After Taking a Closer Look at This Photo!   JustPerfact USAUndoNews SharperChrissy Metz Is So Skinny Now And Looks Like A Model (Photos)News SharperUndoBleacherBreaker4 Sisters Take The Same Picture For 40 Years. Don’t Cry When You See The Last One!BleacherBreakerUndoMisterStoryWoman files for divorce after seeing this photoMisterStoryUndoZen HeraldEllen Got A Little Too Personal With Blake Shelton, So He Said ThisZen HeraldUndoBeach RaiderMom Belly Keeps Growing, Doctor Sees Scan And Calls CopsBeach RaiderUndo Refinitiv buys the Red Flag Group as it expands due diligence offering The Red Flag Group is a Hong Kong-based compliance risk firm with offices located in the US, Asia, the Middle East and Europe. With more than 900 clients, its products include Integrawatch, which monitors negative compliance issues, and Compliance Desktop, a platform used to identify and manage risk. Phil Cotter, managing director of Refinitiv’s risk business said: “The Red Flag Group’s strong corporate customer base and customer-facing technology complement our traditional strength in financial services, rich and diverse datasets and automation capabilities.” Data provider Refinitiv is set to expand its due diligence offering as it announces its acquisition of risk firm the Red Flag Group. (Photo: Getty images) whatsapp Show Comments ▼last_img read more

first_imgAlcohol & Substance Abuse | Nation & World | Pew Charitable TrustsOverdose deaths fall in 14 states — including AlaskaFebruary 22, 2018 by Christine Vestal, Stateline Share:A woman is loaded into an ambulance in Huntington, West Virginia, following an opioid overdose rescue. Experts say a decline in overdose deaths in 14 states is due in part to increased use of the overdose antidote naloxone. (Photo by Pew Charitable Trusts)New provisional data released this month by the Centers for Disease Control and Prevention shows that drug overdose deaths declined in 14 states during the 12-month period that ended July 2017, a potentially hopeful sign that policies aimed at curbing the death toll may be working.In an opioid epidemic that began in the late 1990s, drug deaths have been climbing steadily every year, in nearly every state. A break in that trend, even if limited to just 14 states, has prompted cautious optimism among some public health experts.“It could be welcome news,” said Caleb Alexander, an epidemiologist and co-director of Johns Hopkins University’s Center for Drug Safety and Effectiveness.“If we’re truly at a plateau or inflection point, it would be the best news all year,” he said. “But we’re still seeing rates of overdose that are leaps and bounds higher than what we were seeing a decade ago and far beyond any other country in the world.”The reported drop in overdose deaths occurred in Wyoming, Utah, Washington, Alaska, Montana, Mississippi, Kansas, Rhode Island, Oregon, California, Tennessee, Massachusetts, Arizona and Hawaii. That compares with declines in only three states — Nebraska, Washington and Wyoming — reported for an earlier 12-month period that ended in January 2017.But even as more states saw a drop in deaths, several saw death spikes of more than 30 percent, most likely due to the increasing presence of the deadly synthetic drug fentanyl in the illicit drug supply, drug experts say. Those are Delaware, Florida, New Jersey, Ohio and Pennsylvania, along with the District of Columbia.Published monthly since August, the new CDC statistics are a compilation of death certificate data from all 50 states for a rolling 12-month period ending seven months prior to release of each report. The seven-month delay is roughly the amount of time it takes for states to complete death investigations and report causes of death, and for the CDC to compile the data.Previously, the CDC only made death data available once a year and it was 12 to 14 months behind. In a fast-moving opioid scourge, epidemiologists say the increased frequency of overdose death reporting is a welcome improvement.Farida Ahmad, a public health expert with the CDC, cautioned that the monthly provisional death numbers are subject to change because as many as 2 percent of death certificates for the time period have not been reported. A final death count for 2017 will not be available until November, she said.Increased VolatilityIn Alaska, where deaths declined more than 11 percent between the 12-month period ending July 2016 and the 12-month period ending July 2017, the state’s public health chief, Jay Butler, said the trend has been cause for some optimism.The greatest portion of that decline was in prescription opioids, drugs such as OxyContin, Percocet and Vicodin, Butler said.“And we may be seeing a plateauing, if not a decline, in overdose deaths from heroin,” he added. “The bad news is that we’re seeing more deaths from fentanyl.”Indeed, fentanyl-related deaths spiked more than 70 percent nationwide in the 12-month period ending July 2017, according to the report.“Using illicit drugs has always been a game of roulette,” Butler said. “There’s just more bullets in the chamber now.“When the epidemic was driven primarily by prescription opioids, we saw a smoldering and chronically escalating problem,” he said. “Now we’re seeing outbreaks and clusters of death resulting from bad batches of heroin or counterfeit pills laced with fentanyl.”Still RisingThe recent drop in opioid deaths in some states might be significant, experts say, but they caution it should be seen in the context of the worst drug death epidemic in U.S. history.In 2016, the annual overdose death count reached nearly 64,000, more than three times as many as in 1999. It surpassed the number of fatalities from automobile crashes and homicides, becoming the No. 1 cause of death among Americans 50 and younger.Aside from the 14 states seeing declines, there are few signs of relief ahead.Nationwide, the death toll is still rising, although possibly at a lower rate than in the past two years. According to the CDC’s current provisional report, the total number of overdose deaths increased 14 percent in the 12-month period ending in July 2017, compared to a 21 percent increase in the 12- month period that ended in January 2017.One reason could be a decline in the availability of prescription painkillers. Even as overdose deaths spiraled over the last five years, the rate of prescribed opioid consumption began to decline.That could mean lower rates of heroin use, addiction and overdose deaths in the future, Alexander said. A vast majority — 86 percent — of young, urban injection drug users started misusing prescription opioids before turning to heroin, according to surveys by the National Institute on Drug Abuse.Another likely reason for a tapering in death counts is the widespread use of the overdose antidote naloxone, public health experts say.“It’s hard to imagine how high the death toll would be without naloxone,” said Michael Kilkenny, the Cabell-Huntington public health director in West Virginia.“It’s a little too soon to tell,” he said, “but we may be seeing the beginning of a decline in the number of deaths in Huntington,” a small city that has the highest overdose death rate in West Virginia, the state with the highest overdose death rate in the country.Share this story:last_img read more

first_imgCorrection: An earlier version of this story incorrectly attributed findings of fact to the Texas Medical Board. The findings of fact were issued by the State Office of Administrative Hearings, and were incorporated into the board staff’s proposed decision, along with the board staff’s proposed sanctions. In the board’s filings last summer, it accused Burzynski of unethical and unprofessional conduct regarding clinical trials of gravely ill patients. Those charges included improper care, deceptive advertising, and the use of unlicensed staff, among others.In the findings of fact issued Wednesday, the board’s staff quoted findings of fact issued by the Texas State Office of Administrative Hearings, which found insufficient evidence of deceptive advertising. However, it found, among other violations, that Burzynski in at least one case failed to follow the treatment protocol to which a patient initially consented, and that one of Burzynski’s clinicians misrepresented herself as being authorized to practice medicine.Elsewhere in the findings of fact, the Office of Administrative Hearings found that there was insufficient evidence to suggest patients suffered harm as a result of the violations.“Respondent’s continued practice in treating advanced cancer patients is a present value to the cancer community,” it read. “Respondent’s treatments have saved the lives of cancer patients, both adults and children, who were not expected to live.”In addition to the recommended fines, the board’s staff proposed ordering Burzynski to submit all patient-consent forms to the Board’s medical director for review, and complete a course in ethics. A long-running battle between the Texas Medical Board and controversial Houston doctor Stanislaw Burzynski could be coming to a head.The board’s staff said this week that it had proposed $380,000 in fines and a stiff set of sanctions for Burzynski’s failure to adhere to proper medical procedures in treating cancer patients. The decision is preliminary, and will be submitted and formally reviewed on March 3.The recommendations formally called for the revocation of Burzynski’s license, but the board’s staff then recommended suspending that sanction, pending a probationary period of at least four years, during which the physician’s work would undergo strict monitoring.advertisement By Bob Tedeschi Feb. 16, 2017 Reprints Dr. Stanislaw Burzynski, center, seen here in 1997, during a news conference and surrounded by supporters. David J. Phillip/AP To help cancer patients, lawmakers pushed access to a controversial doctor center_img Burzynski declined comment, but his lawyer, Melanie Rubinsky, said the physician would submit his own proposed ruling in advance of the March 3 board meeting. “The proposed order is not final until the full board signs off on it,” she said. “It’s not a done deal.”Under Texas law, even if the board adopts the staff recommendations, Rubinsky said Burzynski could pursue a court appeal.advertisement HealthTexas board recommends sanctions against controversial cancer doctor Related: Tags cancerphysicianslast_img read more

first_img Tags Donald Trumpdrug pricingMedicarepharmaceuticals Related: There are ways to fix this problem. The U.S. could allow drug wholesalers to import generic drugs that have been approved in other developed countries when the price of U.S. generics spikes. It could allow Americans to import prescription drugs from abroad. It could prohibit drug makers from selling their products at higher prices in the U.S. than they do elsewhere. Trump’s plan could have included one or more of these ideas or it could have explained why they won’t work. It does neither. President Donald Trump delivers a speech on prescription drug prices at the White House Friday. Chip Somodevilla/Getty Images Related: Leave this field empty if you’re human: Governmentally provided insurance isn’t the solution to our problems; it is the source of our problems.The best, and probably the only, way to discipline drug prices is to give seniors the power to decide which drugs they want and how much they are willing pay for them. Trump could do this by putting Medicare on a fixed budget and giving the program’s dollars to eligible seniors, who would then decide how to spend them. With almost 60 million bargain-hungry seniors shopping for drugs, medical services, and insurance policies, the impact on health care prices and spending would be immediate and enormous.Trump’s American Patients First plan isn’t the worst thing we’ve seen, but it’s not going to bring down most drug prices, at least in the short run. More radical reforms are needed to do that.Charles M. Silver is professor of government at the School of Law at the University of Texas at Austin. David A. Hyman is professor of law at the Georgetown University Law Center. Both are adjunct scholars at the Cato Institute and authors of “Overcharged: Why Americans Pay Too Much for Healthcare” (Cato Institute, June 2018).Editor’s note: The authors updated the article to better reflect the potential promise of the drug pricing plan. Please enter a valid email address. Trump promised to bring pharma to justice. His speech sent drug stocks soaring By Charles M. Silver and David A. Hyman May 14, 2018 Reprints What about pharmacy benefit managers? Although the president claimed to hate middlemen and promised that “they won’t be so rich anymore,” here, too, Trump’s plan offers no significant changes. It proposes to base copays by Medicare Part D enrollees on the discounted prices that pharmacy benefit managers pay, instead of the phony list prices the drug makers put out. It also proposes to cap Medicare beneficiaries’ total out-of-pocket drug costs. The plan gives no estimate of the savings the first proposal will generate, and the second proposal will cost Medicare more. Both ideas appear to be small potatoes anyway. In 2015, beneficiaries who exceeded the existing catastrophic threshold spent about $1.2 billion, a small fraction of the $110 billion that Medicare Part D shelled out in total for prescription drugs.advertisement [email protected] [email protected] center_img After President Trump announced his plan for reining in prescription drug prices, shares in drug companies and pharmacy benefit managers spiked. Why? Based on Trump’s campaign rhetoric — drug companies are “getting away with murder,” Medicare should bargain down prices, etc. — Wall Street feared that big changes were afoot. But Trump’s plan (titled “American Patients First“) doesn’t propose any big changes, so investors were relieved and stock prices jumped up. Trump even endorsed two policies that could modestly increase drug makers’ profits.Start with the subsidies we give drug makers by paying high prices for drugs that are much cheaper abroad. Trump derided this “global freeloading,” saying, “It’s unfair, it’s ridiculous, and it’s not going to happen any longer.” But his plan attempts to fix the problem by making foreign prices higher — not by reducing prices in the U.S.But even if the president somehow gets other countries to pay more for prescription drugs, it is Economics 101 that profit-maximizing pharmaceutical companies won’t respond by selling their products more cheaply in the U.S. Instead, they’ll keep the extra money they extract from foreigners and continue gouging Americans as well.advertisement Newsletters Sign up for D.C. Diagnosis An insider’s guide to the politics and policies of health care. Excessive reliance on third-party payment eliminates the natural ceiling on prices that operates in other markets, which is tied to consumers’ willingness to pay. This is a primary driver of rising health care costs. By reducing or eliminating beneficiaries’ out of pocket costs, Trump’s plan will only make this problem worse. To be fair, the plan will cap increases in the prices of drugs covered by Part D at the rate of inflation. This will reduce the magnitude of price hikes for existing drugs, but it won’t bring prices down. Nor will it limit the prices that pharmaceutical companies can demand for new medications. This is a serious deficiency because sky-high prices for new drugs are driving up costs significantly.That said, the Trump plan does include several promising ideas. Though individually modest, they may add up in the long run to material savings. The ideas include (1) limitations on the use of FDA processes that have been used to slow generic entry; (2) moving certain drugs and drug families from Part B (where Medicare is purely a price-taker) to Part D (where pharmacy benefit managers and insurers negotiate on behalf of Medicare); and (3) allowing Medicare Part D plans to offer a more limited choice of drugs than is currently the case. It remains to be seen how large an impact these ideas will have.We’ve learned the hard way that Medicare will pay whatever price drug companies ask for their products. In recent years, drug companies have introduced breakthrough treatments for hepatitis C at prices in the $80,000 to $95,000 range. Some programs limited access to these medications, but not Medicare. Instead, in 2015 it spent $8 billion on them after spending nothing on them a few years before. Medicare is paying similar amounts for cancer drugs that offer only marginal improvements over existing treatments.Why is Medicare such a patsy when it comes to drug prices? One important reason is that the Medicare statute prohibits Medicare from negotiating prices. The politics of Medicare are also important. The moment the program refuses to cover an effective medication because of its price, cries of rationing fill the air. From there it’s a predictable cycle: AARP packs the halls of Congress with seniors in wheelchairs, and pandering politicians inundate the Centers for Medicare and Medicaid Services with calls and letters demanding that it pay for the drug. Privacy Policy About the Authors Reprints From drug ads to Medicare moves, 5 policy takeaways from Trump’s drug pricing speech First OpinionWhy does Wall Street love Trump’s ineffective drug-price plan? David A. Hyman Trump’s plan also ignores the most obvious strategy for reducing the need for pharmacy benefit managers: moving drugs more quickly from prescription status to over-the-counter or behind-the-counter status. When consumers spend their own money, they shop for deals and generally stay away from goods that are overpriced. These actions pressure manufacturers to bring prices down, and the niche filled by pharmacy benefit managers disappears.Does anyone think it is an accident that the only overpriced commodities sold in drugstores are branded prescription drugs that are covered by insurance? Making more drugs available without prescriptions would save consumers the cost of doctors’ visits, too.Trump also promised to reduce consumers’ out-of-pocket costs. He proposes to accomplish this by eliminating cost-sharing on generic drugs for low-income Medicare beneficiaries and for people who obtain drugs from certain hospitals and clinics through the 340B program. Because these reforms are intended to insulate consumers from drug costs, they are likely to push prices up — not down — by spurring demand and eliminating any incentive to comparison shop. When consumers pay nothing for drugs at the point of sale, they will use more of them and won’t care how much money insurers are spending. Charles M. Silverlast_img read more

first_img @adamfeuerstein Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED What is it? Tags biotechnologypharmaceuticals What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. And now, your nominees for worst biopharma CEO of 2018. Let the voting begin! center_img Adam’s Take Hyacinth Empinado/STAT [email protected] Adam Feuerstein About the Author Reprints Yesterday, I lauded the best biopharma CEOs of 2018. Today, I give a side-eye glance to the worst.To land on this ignominious list, biopharma CEOs had to screw up so badly over the past 12 months to set off my outrage alarm. Serial incompetence is also a qualifier. You’d think I would have trouble finding four nominees. You’d be wrong. The hard part for me is narrowing down the list to just four finalists. Enjoy your reading. You’ll get a chance to vote at the bottom of this post. Log In | Learn More By Adam Feuerstein Dec. 13, 2018 Reprintslast_img read more

first_img Keywords Marketwatch A strong rally in the price of oil helped Canada’s main stock index stay out of the red Tuesday, as Wall Street indices hit another all-time high. The S&P/TSX composite index was up 1.59 points to 16,319.24, with rising energy stocks offsetting losses in the materials sector. TSX gets lift from financials, U.S. markets rise to highest since March S&P/TSX composite hits highest close since March on strength of financials sector Share this article and your comments with peers on social media Facebook LinkedIn Twittercenter_img Related news Toronto stock market dips on weakness in the energy and financials sectors Canadian Press The February crude contract surged US$1.23 to US$62.96 per barrel. “There’s been better price action within a lot of commodities, particularly within the energy complex,” said Sid Mokhtari, executive director at CIBC Capital Markets. “It may appear to be overbought but the sentiment behind it continues to improve and help the energy sector in Canada and the U.S. And that’s something that had been lagging in the past.” South of the border, the U.S. stock market is marking its longest New Year’s winning streak in eight years. In New York, the Dow Jones industrial average advanced 102.80 points to 25,385.80. The S&P 500 index added 3.58 points to 2,751.29 and the Nasdaq composite index was up 6.19 points to 7,163.58. On the Canadian corporate front, shares of Royal Bank of Canada were up 53¢, or 0.51%, to $104.84 Tuesday amid comments by RBC CEO Dave McKay that Canadian banks are expecting some short-term pain from U.S. President Donald Trump’s tax overhaul but a significant lift on future earnings. McKay said RBC expects a writedown of US$150 million, plus or minus 10% or 15%, in the bank’s first quarter but is expecting an annual tax-positive benefit of US$150 million to US$200 million going forward. Read: Banks see initial writedowns, future earnings bump under Trump tax changes Meanwhile, Restaurant Brands International Inc.’s stock was down 38¢, or 0.49%, to $77.95 as a social media movement encouraged people to join “No Timmies Tuesday” and instead visit independent coffee shops. Many people are denouncing the coffee-and-doughnut chain and participating in a boycott until some Ontario franchisees and their corporate parent, RBI, come up with a different solution to offset the province’s minimum wage hike than clawing back employee benefits. In currency markets, the Canadian dollar closed at an average trading value of US80.30¢, down 0.20 of a U.S. cent. Elsewhere in commodities, the February natural gas contract was up US9¢ to US$2.92 per mmBTU. The February gold contract fell US$6.70 to US$1,313.70 an ounce and the March copper contract was down a cent at US$3.22 a pound.last_img read more

first_imgFacebookTwitterWhatsAppEmail The Combined Disabilities Association, and the University of the West Indies (UWI) Development and Endowment Fund have received grants totaling US$15,000, from the Jamaica Women of Washington Association (JWOW).The Washington-based organisation has awarded a grant of US$10,000 to the Combined Disabilities Association and US$5,000 to the UWI Endowment Fund.Making the announcement at a fund-raising event staged by JWOW on June 8, at the Four Seasons Hotel, downtown Washington, D.C., President, Dr. Jacqui Watson said the organization is very pleased to assist these two organizations, so they could continue to assist in promoting healthy lifestyles.Dr. Watson pointed out that the Combined Disabilities Association would use the grant to host physical activity sessions throughout the island for the disabled and develop appropriate educational materials and convert them into Braille. The funds will also be used to continue the structured exercise and proper nutrition programme.Lorna Golding (second left), wife of Prime Minister Bruce Golding with Washington, D.C, First Lady, Michelle Fenty (third left); Jamaica’ s Ambassador to the United States, Anthony Johnson and Dr. Jacqui Watson, President of the Jamaica Women of Washington (JWOW). They were attending a fund-raising event staged by the JWOW on June 8 at the Four Seasons Hotel in downtown Washington, D.C.She also noted that the grant to the UWI Development and Endowment Fund would be used by the Tropical Medicine Research Institute for research work.In his message, read by Jamaica’s Ambassador to the United States, Anthony Johnson, Prime Minister Bruce Golding commended JWOW for focusing on health issues.“Your organization’s focus on health and social issues, coincides with the government’s own agenda for national development. We welcome your development in these areas and commend your organization,” he said.The JWOW has contributed US$175,000 to a number of charitable organizations in Jamaica over the past five years, including Jamaica Aids Support, Mensana Community for the Upliftment of the Mentally Ill, Westmoreland Association for Street People, Children First, Women’s Media Watch, Family and Parenting Centre, and Western Society for the Upliftment of Children.Also attending the event were: Lorna Golding, wife of Prime Minister Bruce Golding; Mayor of Washington, Adrian Fenty, and members of the Caribbean Diplomatic Corps. Advertisements RelatedOrganisations Receive US$15,000 from JWOW RelatedOrganisations Receive US$15,000 from JWOWcenter_img Organisations Receive US$15,000 from JWOW UncategorizedJune 11, 2008 RelatedOrganisations Receive US$15,000 from JWOWlast_img read more

first_imgCorona proof dining out with online tool Scientists of Wageningen University & Research, TU Delft and Erasmus MC have developed an online tool that helps determine how indoor spaces can be designed and used corona proof. With the OpenSmartTogether tool, restaurant owners can limit the risks of the spreading of the coronavirus in their restaurant. The researchers are inviting restaurant owners to participate in an online pilot.How do we restart society responsibly after the lockdown? That is the big question facing the government and various sectors. “Until now, the policy has mainly been a one-size-fits-all approach, while tailor-made solutions are also possible”, says project leader Quirine ten Bosch, an infectious diseases modeller at Wageningen University & Research. The OpenSmartTogether (in Dutch: SamenSlimOpen) tool helps to find out with which combination of solutions and measures the chance of spreading the coronavirus in a specific indoor space is as low as possible.This month, the researchers are going to test the OpenSmartTogether tool virtually with restaurant owners who have registered for it. All kinds of factors such as the number of square metres, the ventilation, the number of guests and how long they stay seated and the number of shifts are included in the tool. “These are the factors that we can adjust to achieve the ultimate goal: to reduce the risks of the coronavirus spreading in indoor areas to such an extent that people can stay there responsibly”, says Ten Bosch.Knowledge combinedIn the OpenSmartTogether tool, virological and epidemiological knowledge is combined with data from crowd modelling research. If everything goes according to plan, the tool will be available online for all restaurant owners in April. As soon as restaurants are allowed to reopen, restaurant owners can then use the tool to take targeted measures to minimise the risk of the coronavirus spreading in their specific location.In the next phase, the tool will be further developed for other indoor spaces, such as shops and classrooms. “With adjustments, the tool can also be used in the future for other infectious diseases”, says Ten Bosch. /Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here. Why?Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don’t put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!Tags:coronavirus, covid-19, future, Government, infectious diseases, Internet, online, pilot, project, research, restaurant, Society, space, university, University of Wageningenlast_img read more

first_imgPositive COVID-19 Case Update 29 May Department of the Chief Minister and CabinetOne new COVID-19 case has been recorded in the Northern Territory in the past 24 hours.A 33-year-old female, who arrived on the repatriation flight from New Delhi on 23 May 2021 has tested positive for COVID-19. She is asymptomatic and is under the care of NT Health at the NT Centre for National Resilience.Since repatriation flights to the Northern Territory began on 23 October 2020:• 7,746 international arrivals have undertaken quarantine at the Howard Springs Centre for National Resilience.• A total of 125 positive COVID-19 cases have been reported from international repatriation.The total number of cases diagnosed in the Northern Territory is 174. All cases have been related to international or interstate travel, with no cases of community transmission. /Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here. Why?Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don’t put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!Tags:AusPol, Australia, community, covid-19, Government, health, Howard, New Delhi, Northern Territory, NT Health, quarantine, resilience, travellast_img read more